Women's health firm AccuBoost is directing attention to a recent study in Brachytherapy on the successful use of its high-dose-rate noninvasive breast brachytherapy technology for tumor bed boost with whole-breast radiation therapy.
The results were an update from a multi-institutional study of the feasibility and reproducibility of a noninvasive tumor bed boost. The researchers found that 97.4% of the 518 early-stage breast cancer patients had excellent/good breast cosmesis after being treated with AccuBoost for tumor bed boost in combination with whole-breast radiation therapy after lumpectomy. In addition, 97.6% did not have breast cancer recurrence.
A total of 15 academic and community hospitals and freestanding radiation oncology centers contributed data to the study, which was conducted from July 2007 to February 2015. The researchers found no statistical differences in cosmesis between the academic and community centers or related to the timing of the AccuBoost treatment.
The study, which was led by Dr. Jessica Schuster of Virginia Commonwealth University, was published online October 6 (Brachytherapy).
